Navigation Links
Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
Date:10/11/2010

MANHATTAN BEACH, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that President and CEO Robert Brooke will present a company overview during Precision IR's Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference.  The webcast presentation will be available Wednesday, October 13, at 1:00 p.m. Eastern time (10:00 a.m. Pacific time) by visiting the company's website at www.genesis-biopharma.com and an archive of the presentation will be available for 90 days.  

"We look forward to our presentation at the Informed Investors Conference as an opportunity to broaden our investment-community exposure during a pivotal period in our development," said Robert Brooke, President and CEO of Genesis Biopharma.  "Following the recent completion of a $700,000 financing, we are well positioned to advance development of our promising anti-CD55 antibody program."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit www.genesis-biopharma.com.

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential,, "suggests," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Announces $700K Private Financing
2. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
3. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
4. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
5. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
6. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
7. Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference
8. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
9. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
10. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
11. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Kansas City, Missouri (PRWEB) , ... May 27, 2016 , ... ... Market Development Manager, Turf and Ornamental Products. , In his 15-year career with PBI-Gordon, ... as Herbicide Product Manager, where he was integral in the development and launch of ...
(Date:5/26/2016)... and READING, England , May ... http://www.indegene.com ), a leading global provider of clinical, ... and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ), ... throughout the product lifecycle, today announced the extension ... IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... are used in leading laboratories all over the globe. Their cute firefly logo ... to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. ...
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics ... of the National Coordinator for Health IT (ONC) outlining a measurement approach to ... were available when and where it was needed. The organization of health informatics ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):